A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a Multiclade HIV-1 DNA Plasmid Vaccine, VRC-HIVDNA006-00-VP, In ... View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2002-2003

ABSTRACT

This study will test the safety of an experimental vaccine against HIV and examine whether it induces an immune response to HIV. A vaccine is a substance given to try to create resistance or immunity to a disease or infection. The vaccine in this study is made from DNA (genetic material) of four HIV proteins called gag, pol, Nef, and Env. Injected into a human, the viral DNA instructs the body to make small amounts of some HIV proteins. This study will see if the body then creates an immune response to these proteins. Study participants cannot catch HIV or AIDS from the DNA vaccine or any proteins made from it. Healthy normal volunteers between 18 and 60 years of age may be eligible for this study. Candidates will provide a medical history, including information on sexual behaviors and drug use. They will have a physical examination and blood and urine tests. Women will also have a pregnancy test. Women enrolled in the study must either be infertile (e.g., due to menopause or hysterectomy) or must agree either to abstain from heterosexual sex or to practice birth control for at least 21 days before beginning the study and throughout its duration. Participants will be randomly assigned to receive either the experimental vaccine or a placebo (a control substance made up of an inactive salt solution) and will be divided into three groups, based on their entry into the study. Of the first seven people enrolled (Group 1), five will receive a 2-mg dose of vaccine and two will receive placebo. If the vaccine is safe at this dose, then in Group 2, five people will receive a 4-mg dose of vaccine and two will receive placebo. If this dose is safe, then in Group 3, thirty people will receive an 8-mg dose of vaccine and six will receive placebo. All participants will receive three injections in an upper arm muscle-one injection a month for three months-with a needle-less device called a Biojector 2000® (Registered Trademark). At the time of each injection, participants will be observed for at least 1 hour after immunization. At home, they will record their temperature and any symptoms they may experience, including any effects at the injection site, for at least 2 days, or as long as the symptoms remain. If symptoms occur, participants will report them immediately to the clinic staff and, if necessary, come to the clinic for an examination. Participants will have about 10 clinic visits during the study. Most visits will last about 2 hours; those on vaccination days will last about 4 hours. At each visit, participants will be checked for health changes or problems and will be asked about medications they are taking. Blood will be drawn for immune system testing. Additional laboratory tests may be requested between visits. Participants will be tested several times for HIV, will be questioned about their sexual behavior and drug use, and about social effects they may have experienced from their participation in the study. Some of the blood drawn for this study will be used to test for HLA type-a genetic test of immune system markers. For research, HLA testing is sometimes used to try to identify factors associated with the progression of HIV disease or related conditions. Detailed Description This is a Phase I, randomized, controlled, double-blinded, dose-escalation study to examine tolerability, dose, and immune response of an HIV DNA plasmid vaccine. The hypothesis is that this vaccine will be safe for human administration and elicit immune responses to HIV. The primary objective is to evaluate the safety and tolerability in humans of VCR-HIVDNA006-00-VP and secondary objectives are to evaluate the immuogenicity of the vaccine and social impact of participating in an HIV-1 vaccine trial. A Data and Safety Monitoring Board (DSMB) will review protocol results twice prior to dose escalation to the 8 mg dose level. More... »

URL

https://clinicaltrials.gov/show/NCT00045838

Related SciGraph Publications

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3177", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3053", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "This study will test the safety of an experimental vaccine against HIV and examine whether it induces an immune response to HIV. A vaccine is a substance given to try to create resistance or immunity to a disease or infection. The vaccine in this study is made from DNA (genetic material) of four HIV proteins called gag, pol, Nef, and Env. Injected into a human, the viral DNA instructs the body to make small amounts of some HIV proteins. This study will see if the body then creates an immune response to these proteins. Study participants cannot catch HIV or AIDS from the DNA vaccine or any proteins made from it. Healthy normal volunteers between 18 and 60 years of age may be eligible for this study. Candidates will provide a medical history, including information on sexual behaviors and drug use. They will have a physical examination and blood and urine tests. Women will also have a pregnancy test. Women enrolled in the study must either be infertile (e.g., due to menopause or hysterectomy) or must agree either to abstain from heterosexual sex or to practice birth control for at least 21 days before beginning the study and throughout its duration. Participants will be randomly assigned to receive either the experimental vaccine or a placebo (a control substance made up of an inactive salt solution) and will be divided into three groups, based on their entry into the study. Of the first seven people enrolled (Group 1), five will receive a 2-mg dose of vaccine and two will receive placebo. If the vaccine is safe at this dose, then in Group 2, five people will receive a 4-mg dose of vaccine and two will receive placebo. If this dose is safe, then in Group 3, thirty people will receive an 8-mg dose of vaccine and six will receive placebo. All participants will receive three injections in an upper arm muscle-one injection a month for three months-with a needle-less device called a Biojector 2000\u00ae (Registered Trademark). At the time of each injection, participants will be observed for at least 1 hour after immunization. At home, they will record their temperature and any symptoms they may experience, including any effects at the injection site, for at least 2 days, or as long as the symptoms remain. If symptoms occur, participants will report them immediately to the clinic staff and, if necessary, come to the clinic for an examination. Participants will have about 10 clinic visits during the study. Most visits will last about 2 hours; those on vaccination days will last about 4 hours. At each visit, participants will be checked for health changes or problems and will be asked about medications they are taking. Blood will be drawn for immune system testing. Additional laboratory tests may be requested between visits. Participants will be tested several times for HIV, will be questioned about their sexual behavior and drug use, and about social effects they may have experienced from their participation in the study. Some of the blood drawn for this study will be used to test for HLA type-a genetic test of immune system markers. For research, HLA testing is sometimes used to try to identify factors associated with the progression of HIV disease or related conditions.\n\nDetailed Description\nThis is a Phase I, randomized, controlled, double-blinded, dose-escalation study to examine tolerability, dose, and immune response of an HIV DNA plasmid vaccine. The hypothesis is that this vaccine will be safe for human administration and elicit immune responses to HIV. The primary objective is to evaluate the safety and tolerability in humans of VCR-HIVDNA006-00-VP and secondary objectives are to evaluate the immuogenicity of the vaccine and social impact of participating in an HIV-1 vaccine trial. A Data and Safety Monitoring Board (DSMB) will review protocol results twice prior to dose escalation to the 8 mg dose level.", 
    "endDate": "2003-04-01T00:00:00Z", 
    "id": "sg:clinicaltrial.NCT00045838", 
    "keywords": [
      "Phase I clinical trial", 
      "Evaluate", 
      "safety", 
      "DNA plasmid", 
      "VRC", 
      "adult volunteer", 
      "experimental vaccine", 
      "HIV", 
      "immune response", 
      "vaccine", 
      "substance", 
      "resistance", 
      "immunity", 
      "disease", 
      "infection", 
      "DNA", 
      "gene", 
      "HIV protein", 
      "pol", 
      "Nef", 
      "Env", 
      "viral DNA", 
      "body", 
      "small amount", 
      "protein", 
      "study participant", 
      "HIV or AIDS", 
      "DNA vaccine", 
      "volunteer", 
      "age", 
      "medical history", 
      "sexual behavior", 
      "drug use", 
      "physical examination", 
      "blood", 
      "urine test", 
      "woman", 
      "pregnancy", 
      "infertile", 
      "menopause", 
      "hysterectomy", 
      "abstain", 
      "sex", 
      "practice", 
      "duration", 
      "placebo", 
      "salt solution", 
      "entry", 
      "Group 1", 
      "dose", 
      "Group 2", 
      "Group 3", 
      "injection", 
      "upper arm", 
      "needle", 
      "immunization", 
      "home", 
      "temperature", 
      "symptom", 
      "injection site", 
      "clinic staff", 
      "clinic", 
      "examination", 
      "Ambulatory Care", 
      "visit", 
      "health change", 
      "medication", 
      "system testing", 
      "laboratory test", 
      "social effect", 
      "participation", 
      "HLA type", 
      "immune system", 
      "HLA", 
      "HIV disease", 
      "related condition", 
      "dose escalation study", 
      "tolerability", 
      "HIV DNA", 
      "plasmid", 
      "human administration", 
      "primary objective", 
      "human", 
      "VCR", 
      "secondary objective", 
      "Social Change", 
      "vaccine trial", 
      "Data and Safety Monitoring Board", 
      "protocol", 
      "dose escalation", 
      "dose level"
    ], 
    "name": "A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a Multiclade HIV-1 DNA Plasmid Vaccine, VRC-HIVDNA006-00-VP, In Uninfected Adult Volunteers", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT00045838"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:21", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00000.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.410305.3", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.419681.3", 
        "type": "Organization"
      }
    ], 
    "startDate": "2002-08-01T00:00:00Z", 
    "subjectOf": [
      {
        "id": "sg:pub.10.1038/356152a0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1023052619", 
          "https://doi.org/10.1038/356152a0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1073/pnas.90.24.11478", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1027634738"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1073/pnas.89.23.11277", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038828086"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT00045838"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT00045838'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT00045838'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT00045838'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT00045838'


 

This table displays all metadata directly associated to this object as RDF triples.

128 TRIPLES      16 PREDICATES      112 URIs      100 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT00045838 schema:about anzsrc-for:3053
2 anzsrc-for:3103
3 anzsrc-for:3177
4 schema:description This study will test the safety of an experimental vaccine against HIV and examine whether it induces an immune response to HIV. A vaccine is a substance given to try to create resistance or immunity to a disease or infection. The vaccine in this study is made from DNA (genetic material) of four HIV proteins called gag, pol, Nef, and Env. Injected into a human, the viral DNA instructs the body to make small amounts of some HIV proteins. This study will see if the body then creates an immune response to these proteins. Study participants cannot catch HIV or AIDS from the DNA vaccine or any proteins made from it. Healthy normal volunteers between 18 and 60 years of age may be eligible for this study. Candidates will provide a medical history, including information on sexual behaviors and drug use. They will have a physical examination and blood and urine tests. Women will also have a pregnancy test. Women enrolled in the study must either be infertile (e.g., due to menopause or hysterectomy) or must agree either to abstain from heterosexual sex or to practice birth control for at least 21 days before beginning the study and throughout its duration. Participants will be randomly assigned to receive either the experimental vaccine or a placebo (a control substance made up of an inactive salt solution) and will be divided into three groups, based on their entry into the study. Of the first seven people enrolled (Group 1), five will receive a 2-mg dose of vaccine and two will receive placebo. If the vaccine is safe at this dose, then in Group 2, five people will receive a 4-mg dose of vaccine and two will receive placebo. If this dose is safe, then in Group 3, thirty people will receive an 8-mg dose of vaccine and six will receive placebo. All participants will receive three injections in an upper arm muscle-one injection a month for three months-with a needle-less device called a Biojector 2000® (Registered Trademark). At the time of each injection, participants will be observed for at least 1 hour after immunization. At home, they will record their temperature and any symptoms they may experience, including any effects at the injection site, for at least 2 days, or as long as the symptoms remain. If symptoms occur, participants will report them immediately to the clinic staff and, if necessary, come to the clinic for an examination. Participants will have about 10 clinic visits during the study. Most visits will last about 2 hours; those on vaccination days will last about 4 hours. At each visit, participants will be checked for health changes or problems and will be asked about medications they are taking. Blood will be drawn for immune system testing. Additional laboratory tests may be requested between visits. Participants will be tested several times for HIV, will be questioned about their sexual behavior and drug use, and about social effects they may have experienced from their participation in the study. Some of the blood drawn for this study will be used to test for HLA type-a genetic test of immune system markers. For research, HLA testing is sometimes used to try to identify factors associated with the progression of HIV disease or related conditions. Detailed Description This is a Phase I, randomized, controlled, double-blinded, dose-escalation study to examine tolerability, dose, and immune response of an HIV DNA plasmid vaccine. The hypothesis is that this vaccine will be safe for human administration and elicit immune responses to HIV. The primary objective is to evaluate the safety and tolerability in humans of VCR-HIVDNA006-00-VP and secondary objectives are to evaluate the immuogenicity of the vaccine and social impact of participating in an HIV-1 vaccine trial. A Data and Safety Monitoring Board (DSMB) will review protocol results twice prior to dose escalation to the 8 mg dose level.
5 schema:endDate 2003-04-01T00:00:00Z
6 schema:keywords Ambulatory Care
7 DNA
8 DNA plasmid
9 DNA vaccine
10 Data and Safety Monitoring Board
11 Env
12 Evaluate
13 Group 1
14 Group 2
15 Group 3
16 HIV
17 HIV DNA
18 HIV disease
19 HIV or AIDS
20 HIV protein
21 HLA
22 HLA type
23 Nef
24 Phase I clinical trial
25 Social Change
26 VCR
27 VRC
28 abstain
29 adult volunteer
30 age
31 blood
32 body
33 clinic
34 clinic staff
35 disease
36 dose
37 dose escalation
38 dose escalation study
39 dose level
40 drug use
41 duration
42 entry
43 examination
44 experimental vaccine
45 gene
46 health change
47 home
48 human
49 human administration
50 hysterectomy
51 immune response
52 immune system
53 immunity
54 immunization
55 infection
56 infertile
57 injection
58 injection site
59 laboratory test
60 medical history
61 medication
62 menopause
63 needle
64 participation
65 physical examination
66 placebo
67 plasmid
68 pol
69 practice
70 pregnancy
71 primary objective
72 protein
73 protocol
74 related condition
75 resistance
76 safety
77 salt solution
78 secondary objective
79 sex
80 sexual behavior
81 small amount
82 social effect
83 study participant
84 substance
85 symptom
86 system testing
87 temperature
88 tolerability
89 upper arm
90 urine test
91 vaccine
92 vaccine trial
93 viral DNA
94 visit
95 volunteer
96 woman
97 schema:name A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of a Multiclade HIV-1 DNA Plasmid Vaccine, VRC-HIVDNA006-00-VP, In Uninfected Adult Volunteers
98 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT00045838
99 schema:sdDatePublished 2019-03-07T15:21
100 schema:sdLicense https://scigraph.springernature.com/explorer/license/
101 schema:sdPublisher Nd84ff820556146209161e1de6c12cec4
102 schema:sponsor https://www.grid.ac/institutes/grid.410305.3
103 https://www.grid.ac/institutes/grid.419681.3
104 schema:startDate 2002-08-01T00:00:00Z
105 schema:subjectOf sg:pub.10.1038/356152a0
106 https://doi.org/10.1073/pnas.89.23.11277
107 https://doi.org/10.1073/pnas.90.24.11478
108 schema:url https://clinicaltrials.gov/show/NCT00045838
109 sgo:license sg:explorer/license/
110 sgo:sdDataset clinical_trials
111 rdf:type schema:MedicalStudy
112 Nd84ff820556146209161e1de6c12cec4 schema:name Springer Nature - SN SciGraph project
113 rdf:type schema:Organization
114 anzsrc-for:3053 schema:inDefinedTermSet anzsrc-for:
115 rdf:type schema:DefinedTerm
116 anzsrc-for:3103 schema:inDefinedTermSet anzsrc-for:
117 rdf:type schema:DefinedTerm
118 anzsrc-for:3177 schema:inDefinedTermSet anzsrc-for:
119 rdf:type schema:DefinedTerm
120 sg:pub.10.1038/356152a0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1023052619
121 https://doi.org/10.1038/356152a0
122 rdf:type schema:CreativeWork
123 https://doi.org/10.1073/pnas.89.23.11277 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038828086
124 rdf:type schema:CreativeWork
125 https://doi.org/10.1073/pnas.90.24.11478 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027634738
126 rdf:type schema:CreativeWork
127 https://www.grid.ac/institutes/grid.410305.3 schema:Organization
128 https://www.grid.ac/institutes/grid.419681.3 schema:Organization
 




Preview window. Press ESC to close (or click here)


...